Home > PJ (current issue) > News / News Centre | Search

PJ Online homeThe Pharmaceutical Journal
Vol 276 No 7405 p711
17 June 2006

This article
Reprint   Photocopy

  Acrobat Reader


News summary


Meningitis studies reveal limitations of observational data

Suggestions of harms and benefits resulting from pre-hospital administration of antibiotics to children with suspected meningitis may be statistical artefacts, two papers published in the BMJ suggest.

Observational studies seeking to determine the impact of giving antibiotics to children before admission to hospital have had conflicting results. A confounding factor may be a doctor’s perception of the severity of meningococcal disease, which is likely to determine the choice of treatment.

One study (2006;332:1295) found that administration of parenteral penicillin by GPs was associated with increased odds ratios for death and for complications in survivors. “One likely explanation for the high odds ratio we obtained for mortality is that there is a strong residual selection bias towards giving penicillin to the most severely ill children,” the researchers conclude. They argue that current discrepancies in the data can only be addressed by a randomised controlled trial.

The authors of the second paper (2006;332:1299) were unable to determine whether or not antibiotics given before admission to hospital affected mortality, since their data were consistent with a benefit when a sufficient population of cases was treated. “Confounding by severity is the most likely explanation both for the beneficial effect of oral antibiotics and the harmful effect observed in some studies of parenteral antibiotics,” the authors conclude.

They argue, however, that a trial to answer the question definitely would not be feasible. “It is unlikely that studies of sufficient quality to give evidence of the effectiveness of antibiotic treatment before admission on survival in meningococcal disease will become available in view of the anticipated logistical and ethical difficulties,” they say.

Back to Top


©The Pharmaceutical Journal